Mandate

Vinge advises Fidelio Capital in connection with Nordic Capital’s investment on Greenfood

December 11, 2015

Vinge has advised Fidelio Capital in connection with Nordic Capital’s acquisition of the majority of the shares in the Greenfood group (“Greenfood”), a leading supplier on the attractive market for healthy foods (fruit, vegetables and salads) in the Nordic region.  Greenfood has a turnover of SEK 3.9 billion, approximately 700 employees and its head office is situated in Helsingborg. Greenfood is currently owned by its senior officers, management group and the Swedish family-owned investment company Fidelio Capital. Following the transaction, these parties will remain as stakeholders with Nordic Capital as the majority owner. Nordic Capital’s acquisition is conditional upon consent from the relevant competition authorities.

Vinge’s team consisted of partners Jonas Bergström and Jonas Johansson together with, among others, associates Maria Dahlin, Samra Baytar, Manne Bergström and Karl Samuelsson as well as project assistants Anna Hellof and Josefine Malm.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024